KM Research Hub
← 返回论文库
无 KM 图 入排:排除 图源:可得 入排置信度 0.98

Bowel urgency in ulcerative colitis: effect of baseline urgency and change in urgency in response to mirikizumab.

David B Clemow, Marla C Dubinsky, Simin K Baygani, Bruce E Sands, Anthony Keohane, Silvio Danese, Stefan Schreiber, Alissa J Walsh, Toshifumi Hibi, Theresa Hunter Gibble, Richard E Moses, Simon P L Travis

J Patient Rep Outcomes 9(1) 75

PMID40591171
PMCIDPMC12214185
DOI10.1186/s41687-025-00906-0
发表日期2025-07-01
入排依据:未发现恶性肿瘤人群证据。
已检查 5 张 PubMed Figure,均未识别为 KM 图:Fig. 1:AI 判定为 other;Fig. 2:AI 判定为 other;Fig. 3:AI 判定为 other;Fig. 4:AI 判定为 other;Fig. 5:AI 判定为 other。
摘要

摘要

BACKGROUND: Mirikizumab has demonstrated efficacy in moderately to severely active ulcerative colitis. A 1-2-point change in Urgency Numeric Rating Scale (NRS) score can be meaningful for patients. In these post-hoc analyses, we evaluated the efficacy of mirikizumab compared to placebo by baseline Urgency NRS score groups (0-3, 4-6, and 7-10) and its effect on bowel urgency severity over time. METHODOLOGY: Urgency NRS was measured as a secondary outcome at baseline, week 12, and week 52. Bowel urgency improvement was assessed for patients who achieved and did not achieve multiple efficacy endpoints. Data were analyzed using Fisher's exact test with nonresponder imputation. RESULTS: At weeks 12 and 52, a significantly higher percentage of mirikizumab-treated patients achieved clinical response as well as clinical, endoscopic, and symptomatic remission compared to placebo-treated patients, regardless of baseline Urgency NRS score category (higher proportions versus placebo, delta 9%-45%). Improvement in Urgency NRS score category at weeks 12 and 52 for mirikizumab-treated patients was observed when other efficacy outcomes were achieved (13%-90%) and not achieved (12%-75%). CONCLUSIONS: A greater proportion of mirikizumab-treated patients with ulcerative colitis achieved symptomatic, clinical, and endoscopic remission endpoints compared to placebo-treated patients, regardless of baseline bowel urgency severity. After one year, bowel urgency was improved to a greater extent with mirikizumab than with placebo, even for patients who did not achieve other clinical outcomes. Small improvements in bowel urgency are associated with significant health-related quality-of-life improvements. Monitoring shifts in urgency severity over time using the Urgency NRS can aid in understanding patients' treatment outcomes. TRIAL REGISTRATION: LUCENT-1 (NCT03518086) Registered 04 May 2018 https://clinicaltrials.gov/study/NCT03518086 . LUCENT-2 (NCT03524092) Registered 10 May 2018 https://clinicaltrials.gov/study/NCT03524092 .

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。
其他 Figure(5,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

Fig. 1Fig. 1 Clinical response, clinical remission, or endoscopic remission at weeks 12 and 52. Using NRI, data are shown as the percentage (95% CI) of patients in the modified intention-to-treat population meeting the criteria for clinical response at (A) week 12 and (B) week 52, clinical remission at (C) week 12 and (D) week 52, or endoscopic remission at (E) week 12 and (F) week 52, for patients who received (A, C, E) mirikizumab versus placebo or (B, D, F) mirikizumab versus mirikizumab-to-placebo by Urgency NRS score at induction baseline. * P < 0.05; ** P < 0.01; *** P < 0.001 vs PBO. Week 12: PBO, N = 294; MIRI, N = 868. Week 52: PBO, N = 179; MIRI, N = 365. See the Efficacy Endpoints section for definitions. Abbreviations: CI, confidence interval; IV, intravenous; MIRI, mirikizumab; N , number of patients in the analysis population or the number of patients in each Urgency NRS score grouping; n , number of patients within analyzed group achieving the endpoint of interest; NRI, nonresponder imputation; NRS, Numeric Rating Scale; ns, not significant; SC, subcutaneous; UNRS, Urgency Numeric Rating Scale
非 KM Figure
Fig. 2Fig. 2 (A, B) Symptomatic remission, (C, D) BU remission, or (E, F) IBDQ remission at weeks 12 and 52. Using NRI, data are shown as the percentage (95% CI) of patients in the modified intention-to-treat population meeting the criteria for symptomatic remission at ( A ) week 12 and ( B ) week 52, BU remission at ( C ) week 12 and ( D ) week 52, or IBDQ remission at ( E ) week 12 and ( F ) week 52, for patients who received ( A , C , E ) mirikizumab versus placebo or ( B , D , F ) mirikizumab versus mirikizumab-to-placebo by Urgency NRS score at induction baseline. * P < 0.05; ** P < 0.01; *** P < 0.001 vs PBO. Week 12: Placebo, N = 294; MIRI, N = 868. Week 52: PBO, N = 179; MIRI, N = 365. See the Efficacy Endpoints section for definitions. The number of patients for BU remission is lower because this endpoint was only calculated for patients with an Urgency NRS score ≥ 3 at baseline. Abbreviations: BU, bowel urgency; CI, confidence interval; IBDQ, Inflammatory Bowel Disease Questionnaire; IV, intravenous; MIRI, mirikizumab; N , number of patients in the analysis population OR the number of patients in each Urgency NRS score grouping; n , number of patients within analyzed group achieving the endpoint of interest; na, not applicable (due to small N); NRI, nonresponder imputation; NRS, Numeric Rating Scale; ns, not significant; SC, subcutaneous; UNRS, Urgency Numeric Rating Scale
非 KM Figure
Fig. 3Fig. 3 Shift in Urgency NRS score group from induction baseline to weeks 12 and 52 by treatment and clinical remission status. Purple indicates improvement by 2 group levels, light purple indicates improvement by 1 group level, gray indicates no change, light orange indicates worsening by 1 level, and dark orange indicates worsening by 2 levels. Patients at week 52 were responders to mirikizumab induction therapy at week 12 who were rerandomized to mirikizumab or placebo (treatment withdrawal). Abbreviations: N , number of patients in the analysis population OR the number of patients in each Urgency NRS score grouping; n , number of patients within analyzed group achieving the endpoint of interest; NRS, Numeric Rating Scale; UNRS, Urgency Numeric Rating Scale
非 KM Figure
Fig. 4Fig. 4 Shift in Urgency NRS score from induction baseline to week 52 by treatment and clinical remission status. Purple indicates improvement, gray indicates no change, and orange indicates worsening. An Urgency NRS score of 0 or 1 is considered bowel urgency remission and is noted with a black outline. Patients at week 52 were responders to mirikizumab induction therapy at week 12 who were rerandomized to mirikizumab or placebo (treatment withdrawal). Abbreviations: N, number of patients in the analysis population OR the number of patients in each Urgency NRS score grouping; n, number of patients within analyzed group achieving the endpoint of interest; NRS, Urgency Numeric Rating Scale; UNRS, Urgency Numeric Rating Scale
非 KM Figure
Fig. 5Fig. 5 Clinical relevance of Urgency NRS score improvement shifts. a IBDQ data shown are based on the evaluable overall population (n = 26, 39, 49, 32, and 25 for 1, 2, 4, 6, and 8-point Urgency NRS reductions, respectively), not the n from the individual shift examples shown, with the 8-pt data based upon 8 to 10-pt reductions. b Patients with a low Urgency NRS at baseline have less of an opportunity to have a 3-point improvement
非 KM Figure